Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03905811 · ClinicalTrials.gov registry record · Phase 1
A Pilot Study of Terazosin for Parkinson's Disease
A Phase 1 study of Parkinson Disease, sponsored by Jordan Schultz.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
- 1
- Study location
NCT03905811 is a Phase 1 study of Parkinson Disease that has completed, run by Jordan Schultz. The registered enrollment target is 13 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03905811, a Phase 1 study of Parkinson Disease, has completed, sponsored by Jordan Schultz.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
- 1
- Study location
Study Summary
The TZ-PD trial will be a 1:1 (active:placebo) randomized, double-blind, placebo-controlled Phase II trial to evaluate the safety and tolerability of terazosin for the treatment of PD.
Conditions Studied
Interventions
- DRUG Placebo oral capsule
- DRUG Terazosin 5 MG
Study Locations (1)
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2019-09-24 |
| Est. Completion | 2020-11-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03905811
The ClinicalTrials.gov registry entry for NCT03905811 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (100% lower). The listed sponsor is Jordan Schultz, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo oral capsule is the first listed.
NCT03905811 reports 1 study location spanning 1 distinct geographic area - top geographies include Iowa.
Frequently Asked Questions
What is clinical trial NCT03905811 about?
NCT03905811 is a clinical study titled "A Pilot Study of Terazosin for Parkinson's Disease". The TZ-PD trial will be a 1:1 (active:placebo) randomized, double-blind, placebo-controlled Phase II trial to evaluate the safety and tolerability of terazosin for the treatment of PD.
What is the current status of trial NCT03905811?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2019-09-24. Estimated completion is 2020-11-18.
What conditions does trial NCT03905811 study?
This clinical trial studies the following conditions: Parkinson Disease.
What interventions are being tested in trial NCT03905811?
The interventions under investigation include: Placebo oral capsule (DRUG), Terazosin 5 MG (DRUG).
Who is sponsoring clinical trial NCT03905811?
This trial is sponsored by Jordan Schultz, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03905811 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease
RECRUITING · Phase 1
-
Treating Parkinson's Disease Through Transplantation of Autologous Stem Cell-Derived Dopaminergic Neurons
RECRUITING · Phase 1
-
First-in-Human Single and Multiple Dose of HL-400
RECRUITING · Phase 1
-
Phase 2 Trial of Tributyrin in People With Parkinson's Disease and Cognitive Impairments
RECRUITING · Phase 1
-
[18F]F-DOPA Imaging in Patients With Autonomic Failure
RECRUITING · Phase 1
-
A Study to Assess the Safety of BMS-984923 Compared to Placebo, in People With Parkinson's
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.